Prostaglandin E2 Inhibits Fibroblast to Myofibroblast Transition via E. Prostanoid Receptor 2 Signaling and Cyclic Adenosine Monophosphate Elevation
The DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Myofibroblasts, the hallmark of fibrotic disease, contribute to the pathology of fibrosis by secreting large amounts of extracellular matrix and contributing to alveolar contraction. Myofibroblasts are characterized by the expression of α-smooth muscle actin (α-SMA), a contractile protein normally associated with smooth muscle cells. Transforming growth factor-β1 (TGF-β1) is a well characterized profibrotic cytokine that induces myofibroblast transformation both in vitro and in vivo. We report here that the lipid mediator prostaglandin E2 (PGE2) inhibits TGF-β1–induced expression of α-SMA in primary fetal and adult lung fibroblasts. This inhibition of α-SMA expression is associated with a reduction in the expression of collagen I. Inhibitory actions of PGE2 are mediated via E prostanoid receptor 2 (EP2) signaling, but not by EP3 signaling, and increases in cyclic adenosine monophosphate production. The inhibitory effects of PGE2 on TGF-β1–induced α-SMA expression are mimicked by an EP2 selective agonist, butaprost, and by forskolin-induced direct activation of adenyl cyclase. An EP2 antagonist blocks the inhibitory effects of PGE2, and an EP3 agonist does not inhibit TGF-β1–mediated increases in α-SMA expression. Our results demonstrate that PGE2 inhibits transition of fibroblasts to myofibroblasts by an EP2 receptor-activated pathway. Augmenting this pathway may serve as a potent antifibrotic therapeutic strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostaglandin E2 has similar effects on formation and apoptosis in lung and keloid fibroblasts (145–147).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [147]
Citations
Cites
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243 · cited 1×
“TGF-1 stimulates the expression of -SMA mRNA and protein in myofibroblasts (4, 6, 13 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 2×
“These findings support the prevailing hypothesis that fibrosis is the consequence of dysregulated repair after some form of lung injury ( 2 ).”
BackgroundKhalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.727 · Cited by 505 · cited 1×
“Numerous factors have been identified as promoting the transition of fibroblasts to myofibroblasts, specifically TGF-1, granulocyte macrophage-colony stimulating factor, heparin, and TNF- (12, 29 , 30).”
BackgroundZhang, K., Rekhter, M. D., Gordon, D., & Phan, S. H. (1994) · PubMed · Cited by 480
Wilborn, J., Crofford, L. J., Burdick, M. D., Kunkel, S. L., Strieter, R. M., & Peters-Golden, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117866 · Cited by 392 · cited 3×
“Moreover, fibroblasts cultured from idiopathic pulmonary fibrosis patients exhibit an impaired ability to synthesize PGE2 (21, 22 ), which has been attributed to an inability to appropriately upregulate COX-2 mRNA and protein levels (22, 35).”
BackgroundInfluentialSelf-citationCharacterization of a New Human Diploid Cell Strain, IMR-90
Nichols, W. W., Murphy, D. G., Cristofalo, V. J., Toji, L. H., Greene, A. E., & Dwight, S. A. (1977) · Science · doi:10.1126/science.841339 · Cited by 367 · cited 1×
“Definition of abbreviations: EP, E prostanoid receptor; RT-PCR, reverse transcriptase‐polymerase chain reaction. lung fibroblasts ( 24 ).”
Hansson, G. K., Hellstrand, M., Rymo, L., Rubbia, L., & Gabbiani, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.5.1595 · Cited by 268 · cited 3×
“Few factors have been identified that inhibit the transformation of myofibroblasts (5, 14 , 15, 31).”
BackgroundResultInfluentialFactors influencing myofibroblast differentiation during wound healing and fibrosis.
Desmoulière, A. (1995) · Cell Biology International · doi:10.1006/cbir.1995.1090 · Cited by 265 · cited 3×
“Among the -SMA inducing factors, TGF- 1i s thought to be the most efficient ( 12 ).”
BackgroundInfluentialKeerthisingam, C. B., Jenkins, R. G., Harrison, N. K., Hernandez-Rodriguez, N. A., Booth, H., Laurent, G. J., Hart, S. L., Foster, M. L., & McAnulty, R. J. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64092-8 · Cited by 241 · cited 2×
“Animal models have proven that pharmacologic or genetic blockade of prostaglandin production during the evolution of bleomycin-induced pulmonary fibrosis results in worse fibrotic outcomes ( 35 , 36).”
BackgroundZhang, H.-Y., Gharaee‐Kermani, M., Zhang, K., Karmiol, S., & Phan, S. H. (1996) · Europe PMC (PubMed Central) · Cited by 235
Research works printed but not linked: 13
- 2001, Chest, 120(1 Suppl), 77S
- 1981, Am. J. Pathol., 102, 427
- 1989, Lab. Invest., 60, 643
- 1996, Am. J. Pathol., 148, 527
- 1995, Exp. Nephrol., 3, 134
- 1994, Am. J. Pathol., 145, 114
- 1995, Am. J. Pathol., 147, 352
- 1996, Kidney Int. Suppl., 54, S46
- 1985, Am. Rev. Respir. Dis., 131, 94
- 1998, J. Cell. Biochem., 71, 254, 10.1002/(SICI)1097-4644(19981101)71:2<254::AID-JCB10>3.0.CO;2-L · doi:10.1002/(sici)1097-4644(19981101)71:2<254::aid-jcb10>3.0.co;2-l
- 1993, Am. J. Pathol., 143, 1754
- 1992, Lab. Invest., 67, 716
- 1995, J. Rheumatol., 22, 1876
Cited by
Items 101–200 of 297
Activated Human Lung Fibroblasts Produce Extracellular Vesicles with Antifibrotic Prostaglandins
Lacy, S. H., Woeller, C. F., Thatcher, T. H., Pollock, S. J., Small, E. M., Sime, P. J., & Phipps, R. P. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0248oc · Cited by 52
The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
Kolb, M. R. J., Orfanos, S. E., Lambers, C., Flaherty, K. R., Masters, A., LANCASTER, L. H., Silverstein, A. M., & Nathan, S. D. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02229-8 · Cited by 56
“Preclinical and animal model research supports that treprostinil may exert its therapeutic effect via multiple pathways, including inhibiting fibroblast-to-myofibroblast differentiation, fibroblast proliferation [33, 44, 49, 55], fibroblast migration [32, 39], fibronectin deposition [36], and mast cell-mediator releas…”
BackgroundThe evolution ofin vitromodels of lung fibrosis: promising prospects for drug discovery
Kolanko, E., Cargnoni, A., Papait, A., Silini, A. R., Czekaj, P., & Parolini, O. (2024) · European Respiratory Review · doi:10.1183/16000617.0127-2023 · Cited by 56
“The simplest in vitro models are represented by fibroblasts or alveolar epithelial cells in 2D cultures, which have been useful to understand mechanisms underlying fibrosis development, such as fibroblast to myofibroblast differentiation [21] and EMT [35, 126].”
BackgroundProstaglandin E2 As an Inhibitory Modulator of Fibrogenesis in Human Lung Allografts
Walker, N., Badri, L. N., Wadhwa, A., Wettlaufer, S. H., Peters-Golden, M. L., & Lama, V. N. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0834oc · Cited by 52
Self-citationHuang, S. K., Scruggs, A. M., Donaghy, J., McEachin, R. C., Fisher, A. S., Richardson, B. C., & Peters-Golden, M. L. (2012) · The FASEB Journal · doi:10.1096/fj.11-203323 · Cited by 50
“In lung fibroblasts, we and others have previously shown that PGE2 inhibits fibroblast to myofibroblast differentiation (12), fibroblast proliferation, and fibroblast production of matrix proteins (11, 17).”
BackgroundSelf-citationIdiopathic Pulmonary Fibrosis: New Concepts in Pathogenesis and Implications for Drug Therapy
Horowitz, J. C., & Thannickal, V. J. (2006) · Treatments in Respiratory Medicine · doi:10.2165/00151829-200605050-00004 · Cited by 52
“epithelialization, while collagen secretion stabilizes the contracted tion,[86] and collagen synthesis.”
Self-citationBae, G. H., Kim, Y. S., Park, J. Y., Lee, M., Lee, S. K., Kim, J. C., Kim, J. G., Shin, Y. J., Lee, H., Kim, S., et al. (2022) · Blood · doi:10.1182/blood.2021014283 · Cited by 53
Regulation of myofibroblast dedifferentiation in pulmonary fibrosis
Ju, X., Wang, K., Wang, C., Zeng, C., Wang, Y., & Yu, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02898-9 · Cited by 56
“Prostaglandins, particularly prostaglandin E2 (PGE2), play a significant role in regulating fibroblast differentiation and myofibroblast dedifferentiation primarily through the activation of this pathway [89, 103, 104].”
BackgroundMattyasovszky, S. G., Hofmann, A., Brochhausen, C., Ritz, U., Kühn, S., Wollstädter, J., Schulze‐Koops, H., Müller, L. P., Watzer, B., & Rommens, P. M. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2902 · Cited by 52
Pilatz, A. M. E., Schultheiss, D., Gabouev, A. I., Schlote, N., Mertsching, H., Udo Jonas, A., & Stief, C. G. (2005) · European Urology · doi:10.1016/j.eururo.2005.01.008 · Cited by 48
Lu, D., Aroonsakool, N., Yokoyama, U., Patel, H. H., & Insel, P. A. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.087742 · Cited by 56
“…expression has been noted in rat CFs following myocardial infarction (Swaney et al., 2007), and overexpression of these isoforms can prevent the conversion of CFs (Swaney et al., 2005) and pulmonary fibroblasts (Kolodsick et al., 2003; Liu et al., 2004; Dunkern et al., 2007) to myofibroblasts.”
BackgroundEffects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice
Udalov, S., Dumitrascu, R., Pullamsetti, S. S., Al-tamari, H. M., Weißmann, N., Ghofrani, H. A., Günther, A., Voswinckel, R., Seeger, W., Grimminger, F., et al. (2010) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-10-26 · Cited by 50
“For instance, it was repetitively shown that elevation of cAMP level results in inhibition of lung fibroblast proliferation, migration, transition to myofibroblasts and collagen production [11-13].”
BackgroundDistinct PKA and Epac compartmentalization in airway function and plasticity
Dekkers, B. G. J., Racké, K., & Schmidt, M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.10.006 · Cited by 49
Haag, S., Warnken, M., Juergens, U. R., & Racké, K. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0334-3 · Cited by 47
“…cyclase or indirectly by inhibition of phosphodiesterase can cause inhibitory effects on various functions of pulmonary fibroblasts such as proliferation, collagen synthesis, or myofibroblast transformation (e.g., Kolodsick et al. 2003; Liu et al. 2004; Dunkern et al. 2007; Huang et al. 2007).”
BackgroundFranke, J., Abs, V., Zizzadoro, C., & Abraham, G. (2014) · BMC Veterinary Research · doi:10.1186/1746-6148-10-119 · Cited by 47
“There are several well characterized human fetal lung fibroblast cell lines that are cultured in defined media and for use as in vitro cell model to study airway diseases and remodeling, for example, HFL-1 [6], IMR-90 [7], HEL299, MCR-5 [8], WI-38 [9] and GM 06114 [10].”
BackgroundExtracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis
Burgy, O., Loriod, S., Beltramo, G., & Bonniaud, P. (2022) · Cells · doi:10.3390/cells11071209 · Cited by 51
Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy
Thannickal, V. J., Flaherty, K. R., Martínez, F. J., & Lynch, J. P. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.8.1671 · Cited by 45
Self-citationFranco‐Montoya, M., Boucherat, O., Thibault-Carpentier, C., Chailley‐Heu, B., Incitti, R., Delacourt, C., & Bourbon, J. R. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00034.2011 · Cited by 46
“Prostaglandin E2 has been repeatedly reported to modulate lung inflammation and to prevent the fibroblast-tomyofibroblast transition through E prostanoid receptor 2 (Ptger2) signal (23, 50).”
BackgroundGabasa, M., Royo, D., Molina‐Molina, M., Roca‐Ferrer, J., Pujols, L., Picado, C., Xaubet, A., & Pereda, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065445 · Cited by 45
“dependent [12] and was accompanied by a strong increase in collagen Ia1 expression [1], with greater expression of collagen Ia1 in IPF cultures than in control cultures.”
BackgroundMethodNagahama, K. Y., Togo, S., Holz, O., MAGNUSSEN, H., Liu, X., Seyama, K., Takahashi, K., & Rennard, S. I. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0460oc · Cited by 48
“PGE2 is a major prostanoid produced by fibroblasts, and functions as an endogenous inhibitor of migration (46), differentiation (47), proliferation (48), and matrix production (48).”
BackgroundCOX-2 Is Widely Expressed in Metaplastic Epithelium in Pulmonary Fibrous Disorders
Lappi‐Blanco, E., Kaarteenaho–Wiik, R., Maasilta, P. K., Anttila, S. L., Pääkkö, P. K., & Wolff, H. J. (2006) · American Journal of Clinical Pathology · doi:10.1309/pfgx-clng-2n17-pjx9 · Cited by 43
Zeng, C. C., Liu, J., Zheng, X., Hu, X., & He, Y. (2023) · Respiratory Research · doi:10.1186/s12931-023-02559-3 · Cited by 57
“In addition, activation of the prostaglandin EP2 receptor inhibits fibroblast functions, including proliferation, migration, and the transition from fibroblasts to myofibroblasts [149].”
BackgroundLee, C., Wang, C., Lee, Y., Tsai, Y.-R., & Liu, J.-J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116393 · Cited by 44
“Besides, to determine whether myofibroblast transition increase cell migration activity, we treated cells with prostaglandin E2 (PGE2) which has been observed to inhibit fibroblast to myofibroblast differentiation [36].”
MethodSynthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors
Wu, Y., Tai, H., & Cho, H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.016 · Cited by 42
Feng, F., Wang, Z., Li, R., Wu, Q., Gu, C., Xu, Y., Peng, W., Han, D., Zhou, X., Wu, J., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108669 · Cited by 44
The Role of Airway Myofibroblasts in Asthma
Jendzjowsky, N. G., & Kelly, M. M. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.08.1917 · Cited by 46
Liu, X., Sun, S. Q., & Ostrom, R. S. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090324 · Cited by 42
“We and others have reported that increases in cellular cAMP levels inhibit myofibroblast differentiation (as defined by expression of -SM actin) and have speculated that this effect may be important in attenuating fibrosis (Kolodsick et al., 2003; Liu et al., 2004).”
BackgroundInfluentialO’Reilly, K. M., Phipps, R. P., Thatcher, T. H., Graf, B. A., Kirk, J. V., & Sime, P. J. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00024.2004 · Cited by 40
Sokolova, E., Grishina, Z. V., Bühling, F., Welte, T., & Reiser, G. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00343.2004 · Cited by 40
“Among the regulators of fibroblast functions, PGE2, which is a metabolite of arachidonic acid derived via the cyclooxygenase (COX) pathway, was shown to decrease lung fibroblast proliferation, to reduce collagen levels by inhibition of its mRNA synthesis, to inhibit fibroblast transition into the myofibroblast phenoty…”
BackgroundCai, T., Li, X., Ding, J., Luo, W., Li, J., & Huang, C. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795656001 · Cited by 41
Cai, G., Chou, C., Hu, M., Zheng, A., Reichardt, L. F., Guan, J., Fang, H., Luckhardt, T., Zhou, Y., Thannickal, V. J., et al. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00390.2011 · Cited by 39
Self-citationProstaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced Fibrosis
Nakanishi, T., Hasegawa, Y., Mimura, R., Wakayama, T., Uetoko, Y., Komori, H., Akanuma, S., Hosoya, K., & Tamai, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123895 · Cited by 44
“PGE2 decreases fibroblast proliferation and collagen production [8, 9], inhibits myoblast differentiation [10], and increases collagen degradation [11].”
Patel, J. A., Shen, L., Hall, S., Benyahia, C., Norel, X., McAnulty, R. J., Moledina, S., Silverstein, A. M., Whittle, B. J. R., & Clapp, L. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082372 · Cited by 41
“Importantly, EP2 receptors have a range of inhibitory actions on fibroblast function that could be beneficial in PAH [34,37].”
Higashi, A. Y., Aronow, B. J., & Dressler, G. R. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018060644 · Cited by 38
Sun, G., Wang, R., Li, M., Zhou, S., Zeng, D., Xu, X., & Xu, R. (2015) · International Journal of COPD · doi:10.2147/copd.s74345 · Cited by 39
“11, 12 PGE2 also inhibits LPS-induced NF-κ B activation in monocytes, thereby suppressing TNF-α production while increasing the anti-inflammatory cytokine, interleukin (IL)-10.”
Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition
Milara, J., Serrano, A., Peiró, T., Artigues, E., Gavaldà, A., Miralpeix, M., Morcillo, E. J., & Cortijo, J. (2012) · European Respiratory Journal · doi:10.1183/09031936.00017712 · Cited by 38
“In line with our results, recently, it has been found that PGE2, as a potent cAMP enhancer, may inhibit the activation of fibroblast and the transformation into myofibroblast [33, 34].”
ResultWarsinske, H., Wheaton, A. K., Kim, K. K., Linderman, J. J., Moore, B. B., & Kirschner, D. E. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00183 · Cited by 38
Self-citationParekh, A., Sandulache, V. C., Singh, T., Cetin, S., Sacks, M. S., Dohar, J. E., & Hebda, P. A. (2009) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2008.00445.x · Cited by 37
“This hypothesis is supported by the fact that the myofibroblast phenotype is either transiently expressed or not detected at all in fetal wounds.7,8 PGE2 has been identified as an important mediator of dermal wound healing9,10 with specific effects on fibroblast behavior.15,32,33 Of particular interest is the work by…”
Lynch, J. P., Fishbein, M. C., Saggar, R., Zisman, D. A., & Belperio, J. A. (2007) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.1.3.377 · Cited by 37
Sabatini, F., Petecchia, L., Boero, S., Silvestri, M., Klar, J., Tenor, H., Beume, R., Hatzelmann, A., & Rossi, G. A. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.02.004 · Cited by 39
Lin, Y.-C., Sung, Y. K., Jiang, X., Peters-Golden, M. L., & Nicolls, M. R. (2016) · American Journal of Transplantation · doi:10.1111/ajt.14103 · Cited by 33
“Previous investigations showed that PGE2 signaling through the EP2 receptor inhibits lung myofibroblast differentiation, contraction, and secretion of collagen (26,35).”
BackgroundSelf-citationPGE2 in fibrosis and cancer: Insights into fibroblast activation
Elwakeel, E., Brüne, B., & Weigert, A. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106339 · Cited by 42
Prostaglandins effect on matrix metallopeptidases and collagen in mare endometrial fibroblasts
Szóstek-Mioduchowska, A. Z., Bacławska, A., Rebordão, M. R., Ferreira-Dias, G. M., & Skarzynski, D. J. (2020) · Theriogenology · doi:10.1016/j.theriogenology.2020.04.040 · Cited by 38
Prostaglandin D2 Inhibits Collagen Secretion From Lung Fibroblasts by Activating the DP Receptor
Ayabe, S., Kida, T., Hori, M., Ozaki, H., & Murata, T. (2013) · Journal of Pharmacological Sciences · doi:10.1254/jphs.12275fp · Cited by 38
Henry, P. J. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.051 · Cited by 34
Lee, Y. H., Suzuki, Y., Griffin, A. J., & Day, R. M. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00410.2007 · Cited by 41
“A recent study in MDCK cells showed the requirement of the p42/p44 MAPK pathway for increased expression of COX-2 and subsequent increase in PGE2 (41).”
BackgroundInfluentialShigemitsu, H., & Azuma, A. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283486d52 · Cited by 34
Roberts, M. J., Broome, R., Kent, T. C., Charlton, S. J., & Rosethorne, E. M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0759-2 · Cited by 38
“The endogenous EP receptor agonist PGE2 has been shown to inhibit cellular markers of fibrosis [14, 16], and its synthetic analogue 16, 16dimethyl-PGE2 protects against bleomycin induced injury [24].”
BackgroundCellular Microenvironment Stiffness Regulates Eicosanoid Production and Signaling Pathways
Berhan, A., Harris, T., Jaffar, J., Jativa, F., Langenbach, S. Y., Lönnstedt, I. M., Alhamdoosh, M., Ng, M., Lee, P. V. S., Westall, G. P., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0227oc · Cited by 33
Dietary fat and lipid metabolism in the tumor microenvironment
Goswami, S., Zhang, Q., Celik, C. E., Reich, E. M., & Yilmaz, Ö. H. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188984 · Cited by 41
Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis
Smith, J. N. P., Witkin, M. D., Jogasuria, A. P., Christo, K. F., Raffay, T. M., Markowitz, S. D., & Desai, A. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-68336-0 · Cited by 33
Failla, M., Genovese, T., Mazzon, E., Fruciano, M., Fagone, E., Gili, E., Barera, A., Rosa, C. L., Conte, E., Crimi, N., et al. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0438oc · Cited by 33
Anti-fibrotic effects of theophylline on lung fibroblasts
Yano, Y., Yoshida, M., Hoshino, S., Inoue, K., Kida, H., Yanagita, M., Takimoto, T., Hirata, H., Kijima, T., Kumagai, T., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.018 · Cited by 36
Zhou, S., Liu, Y., Liu, Y., Wu, P., Sun, G., Fei, G., Xu, X., Zhou, X., Zhou, L., & Wang, R. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25420 · Cited by 34
“In addition, PGE2 can also inhibit the transition from the fibroblast to the myofibroblast upon TGF−/− induction [22].”
BackgroundSieber, P., Schäfer, A., Lieberherr, R., Goff, F. L., Stritt, M., Welford, R. W. D., Gatfield, J., Peter, O., Nayler, O., & Lüthi, U. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207872 · Cited by 35
Huang, Q., Liu, X., & Guo, S. (2021) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12423 · Cited by 31
Prostanoids in Asthma and COPD
Zasłona, Z., & Peters-Golden, M. L. (2015) · CHEST Journal · doi:10.1378/chest.15-1029 · Cited by 32
Self-citationProstaglandin D2 Attenuates Bleomycin-Induced Lung Inflammation and Pulmonary Fibrosis
Kida, T., Ayabe, S., Omori, K., Nakamura, T., Maehara, T., Aritake, K., Urade, Y., & Murata, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167729 · Cited by 32
Tsuruda, T., Kato, J., Hatakeyama, K., MASUYAMA, H., Cao, Y., Imamura, T., Kitamura, K., ASADA, Y., & Eto, T. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.11.004 · Cited by 34
“Many of the AM actions have been shown to be mediated by accumulation of intracellular cyclic AMP (cAMP) [12] and consistent with this, significance of cAMP signaling in attenuating the myofibroblastic change was reported in lung fibroblasts [30] and in hepatic stellate cells [31].”
BackgroundHayashi, T., Nishihira, J., Koyama, Y., Sasaki, S., & Yamamoto, Y. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700227 · Cited by 28
“As regards fibrosis, recent publications have indicated that EP2 transduces PGE2 signaling and results in the downregulation of collagen synthesis (Choung et al., 1998; Kolodsick et al., 2003).”
Aronoff, D. M., Serezani, C. H., Carstens, J. K., Marshall, T., Gangireddy, S. R., Peters-Golden, M., & Reddy, R. C. (2007) · PPAR Research · doi:10.1155/2007/52546 · Cited by 28
Self-citationProstaglandin E2 Induces Skin Aging via E-Prostanoid 1 in Normal Human Dermal Fibroblasts
Shim, J.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225555 · Cited by 33
Xiang, Y., Chen, X., Li, J., Wang, S., Faclier, G., MacDonald, J. F., Hogg, J. C., Orser, B. A., & Lu, W.-Y. (2013) · Anesthesiology · doi:10.1097/aln.0b013e31828e180e · Cited by 28
Differential cutaneous wound healing in thermally injured MRL/MPJ mice
Davis, T. A., Amare, M. F., Naik, S., Kovalchuk, A. L., & Tadaki, D. K. (2007) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2007.00266.x · Cited by 26
“Alternatively, potent burn-induced mediators such as prostglandin E2 may interfere with key profibrotic signals and contractile proteins.(28,29) Taken together, these findings could account, at least in part, for the delayed rate of skin wound closure observed in MRL/MpJ mice.”
BackgroundKach, J., Sandbo, N. K., Sethakorn, N., Williams, J. W., Reed, E. B., La, J., Tian, X., Brain, S. D., Rajendran, K., Krishnan, R., et al. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00262.2012 · Cited by 26
“In vitro studies have demonstrated that differentiation, proliferation, and extracellular matrix deposition by pulmonary myofibroblasts can be diminished by activators of cAMP and protein kinase A (PKA) (13, 22, 23, 27, 28, 33, 50, 59), suggesting that cAMP/PKA signaling may be a potential therapeutic target for the t…”
Sugiura, H., Liu, X., Togo, S., Kobayashi, T., Shen, L., Kawasaki, S., Kamio, K., Wang, X., Mao, L. J., & Rennard, S. I. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20825 · Cited by 26
“Action through the E prostanoid2 (EP2) receptor, which signals through Gs and c-AMP, has been suggested to play a particularly important role in this regard (Kolodsick et al., 2003; Moore et al., 2005; White et al., 2005).”
BackgroundPulmonary fibroblasts, an emerging target for anti-obstructive drugs
Racké, K., Haag, S., Bahulayan, A., & Warnken, M. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0264-0 · Cited by 30
“Thus, they were reported to inhibit proliferation (Liu et al. 2004; Huang et al. 2007, Racke et al. 2007b ;H aag et al.2008b ,F ig.4), collagen synthesis (Saltzman et al. 1982; Liu et al. 2004; Huang et al. 2007; Choung et al. 1998), migration (White et al. 2005), chemotaxis (Kohyama et al. 2001) and myofibroblast tra…”
BackgroundParekh, A., Sandulache, V. C., Lieb, A. S., Dohar, J. E., & Hebda, P. A. (2007) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2007.00241.x · Cited by 25
Liu, X., Li, F., Sun, S. Q., Thangavel, M., Kaminsky, J., Balázs, L., & Ostrom, R. S. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00429.2009 · Cited by 24
Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation
Warsinske, H., Ashley, S. L., Linderman, J. J., Moore, B. B., & Kirschner, D. E. (2015) · Bulletin of Mathematical Biology · doi:10.1007/s11538-015-0096-2 · Cited by 26
“PGE2 has been shown to inhibit adhesion signaling and in turn inhibit fibroblast responses to TGF-β1 (Thomas et al. 2007; Kolodsick et al. 2003; Fine et al. 1989; Tian and Schiemann 2010).”
Self-citationSagana, R. L., Mei, Y., Cornett, A. M., Tsui, J. L., Stephenson, D. A., Huang, S. K., Moore, B. B., Ballinger, M. N., Melonakos, J. H., Kontos, C. D., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.004796 · Cited by 23
Self-citationNorambuena‐Soto, I., Núñez-Soto, C., Sanhueza‐Olivares, F., Cancino-Arenas, N., Mondaca‐Ruff, D., Vivar, R., Díaz-Araya, G., Mellado, R., & Chiong, M. (2017) · BioScience Trends · doi:10.5582/bst.2017.01017 · Cited by 24
“Prostaglandin E2 (PGE2) signaling is an important inhibitor of primary fetal and adult lung fibroblast to myofibroblast differentiation, by counteracting the effects of TGF β1 (71).”
Highlights on Future Treatments of IPF: Clues and Pitfalls
Libra, A., Sciacca, E., Muscato, G., Sambataro, G., Spicuzza, L., & Vancheri, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158392 · Cited by 25
“Specifically, EP2 activation inhibits the transformation of fibroblasts into my-ofibroblasts and reduces collagen overproduction [62,63], while DP1 activation decreases the recruitment of inflammatory cells and the synthesis of the extracellular matrix [64].”
BackgroundEicosanoid Control Over Antigen Presenting Cells in Asthma
Debeuf, N., & Lambrecht, B. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02006 · Cited by 27
“It has been shown that PGE2 induces fibroblast apoptosis (38), abolishes myofibroblast differentiation (39) and inhibits proliferation of airway smooth muscle cells (40).”
Wenzel, C., Otto, S., Prechtl, S., Parczyk, K., & Steigemann, P. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.10.003 · Cited by 26
Yoon, Y.-S., Lee, Y.-J., Choi, J.-Y., Cho, M.-S., & Kang, J. L. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0513255 · Cited by 22
“Via EP2-mediated increases in intracellular cAMP, PGE2 directly inhibits major pathobiologic functions of fibroblasts, including chemotaxis, proliferation [7], collagen synthesis [8], and differentiation to myofibroblasts [9].”
BackgroundByun, J. Y., Youn, Y.-S., Lee, Y.-J., Choi, Y., Woo, S.-Y., & Kang, J. L. (2014) · Mediators of Inflammation · doi:10.1155/2014/463524 · Cited by 23
Rosethorne, E. M., & Charlton, S. J. (2018) · Journal of Experimental Pharmacology · doi:10.2147/jep.s159124 · Cited by 25
Current and emerging drugs for idiopathic pulmonary fibrosis
Gharaee‐Kermani, M., Hu, B., Thannickal, V. J., Phan, S. H., & Gyetko, M. R. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.4.627 · Cited by 22
“In addition to its anti-inflammatory activities, PGE 2 may also contribute to antifibrotic effects via inhibition of fibroblast proliferation, migration, contractility and myofibroblast differentiation [187-190] .”
BackgroundSelf-citationMeng, J. P., Ceryak, S. M., Aratsu, Z., Jones, L., Epstein, L. H., & Bouscarel, B. E. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00011.2006 · Cited by 21
“The PGE2 is also a potent inhibitor of fibroblast migration, proliferation and collagen synthesis (23, 24, 54).”
BackgroundEffect of cAMP on TGFβ1-Induced Corneal Keratocyte-Myofibroblast Transformation
Xing, D., & Bonanno, J. A. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2444 · Cited by 21
Cebulla, D., van Geffen, C., & Kolahian, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108313 · Cited by 24
Nakamura, Y., & Shimizu, Y. (2023) · Cells · doi:10.3390/cells12040548 · Cited by 22
“PGE2 has been reported to suppress the proliferation of fibroblasts and their transformation into myofibroblasts and to reduce collagen production [74,76].”
BackgroundMetabolism, fibrosis, and apoptosis: The effect of lipids and their derivatives on keloid formation
Li, C.-Y., Xie, R., Zhang, S., Yun, J., Zhong, A., Cen, Y., & Chen, J. (2024) · International Wound Journal · doi:10.1111/iwj.14733 · Cited by 25
“44,45 Consequently, PGE2 heralds an anti-fibrotic impact across an array of organ systems.”
BackgroundJakieła, B., Gielicz, A., Plutecka, H., Hubalewska, M., Mastalerz, L., Bochenek, G., Soja, J., Januszek, R., Musiał, J., & Sanak, M. (2013) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2013.05.001 · Cited by 20
Emerging drugs for idiopathic pulmonary fibrosis
Thannickal, V. J., Flaherty, K. R., Hyzy, R. C., & Lynch, J. P. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.707 · Cited by 21
“These include inhibitory effects of PGE2 on fibroblast proliferation [135], migration [136], contractility [137] and myofibroblast differentiation [138].”
BackgroundSelf-citationMou, Y., Liu, J., Pan, T. S., Wang, Q., Miao, K., Xu, Y., Xiong, W., & Yu, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111500 · Cited by 20
Laube, M., Stolzing, A., Thome, U. H., & Fabian, C. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.02.023 · Cited by 26
Wehbrink, D., Hässig, M., Ritter, N., Zerbe, H., Bleul, U., & Boos, A. (2007) · Animal Reproduction Science · doi:10.1016/j.anireprosci.2007.04.016 · Cited by 18
Mesenchymal Cell Fate and Phenotypes in the Pathogenesis of Emphysema
Horowitz, J. C., Martínez, F. J., & Thannickal, V. J. (2009) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550902905953 · Cited by 18
“Additionally, these COPD fibroblasts have increased expression of the PGE2 receptors, EP2 and EP4 and decreased responsiveness to exogenous TGF-β1 (17, 109, 110).”
BackgroundSelf-citationRole of coagulation and fibrinolysis in lung and renal fibrosis
Ruppert, C., Markart, P., Wygrecka, M., Preissner, K. T., & Günther, A. (2008) · Hämostaseologie · doi:10.1055/s-0037-1616918 · Cited by 18
Okunishi, K., DeGraaf, A. J., Zasłona, Z., & Peters-Golden, M. L. (2013) · The FASEB Journal · doi:10.1096/fj.13-231720 · Cited by 19
Self-citationChoi, D., Piao, Y. L., Wu, Y., & Cho, H. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.049 · Cited by 18
Lim, X., Bless, D. M., del Río, A. M., & Welham, N. V. (2008) · Annals of Otology Rhinology & Laryngology · doi:10.1177/000348940811700311 · Cited by 18
Wang, Y., Cao, R. Y., Wei, B., Chai, X., Sun, D., Guan, Y., & Liu, X. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2048-9 · Cited by 17
“PGE2 has four G protein-coupled receptors, among which EP2 demonstrates a clear antifibrotic effect through cAMP and its downstream signal molecules [36, 37].”
Feehan, K. T., Bridgewater, H. E., Stenkiewicz-Witeska, J., Maeyer, R. P. H. D., Ferguson, J., Mack, M., Brown, J., Ercoli, G., Mawer, C. M., Akbar, A. N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48138-y · Cited by 19
Xu, Y., Ravid, K., & Smith, B. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708657200 · Cited by 17
COX-2 inhibition attenuates lung injury induced by skeletal muscle ischemia reperfusion in rats
Wang, L., Shan, Y., Ye, Y., Jin, L., Zhuo, Q., Xiong, X., Zhao, X., Lin, L., & Miao, J. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.12.019 · Cited by 17
Wettlaufer, S. H., Penke, L. R. K., Okunishi, K., & Peters-Golden, M. L. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00131.2017 · Cited by 18
“A substantial body of research from our laboratory and others has shown that the lipid mediator PGE2 is capable of opposing many of the fibrogenic actions of TGF -1 (13, 15, 16, 22, 29, 34).”
BackgroundMethodSelf-citationDiverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension
Clapp, L. H., Abu‐Hanna, J., & Patel, J. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-1185-1_5 · Cited by 21
Metadata
- Authors
- Kolodsick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J., & Moore, B. B.
- Affiliations
- University of Michigan (US)
- Department of Internal Medicine, Pulmonary and Critical Care Medicine Division, University of Michigan School of Medicine, Ann Arbor, Michigan
- Corresponding author
- Moore, Bethany B.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11-01
- Volume
- 29
- Issue
- 5
- Pages
- 537-544
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- OpenAlex
- W1995721099
- Cited by
- 294
- References
- 37
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 7 · 2020: 11 · 2019: 15 · 2018: 16 · 2017: 11 · 2016: 10 · 2015: 15 · 2014: 19 · 2013: 16 · 2012: 15
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29ca079046-03)
- National Heart, Lung, and Blood Institute (P50HL56402, HL071586, P50HL056402, P50HL60289, 2T32HL07749, R01HL071586, P50HL060289, T32HL007749)
- National Cancer Institute (CA79046)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- prostaglandin E2, myofibroblast differentiation, cyclic AMP, TGF-β1, alpha-smooth muscle actin, type I collagen, pulmonary fibrosis, antifibrotic therapy, butaprost, adenylate cyclase
- MeSH terms
- Cyclic AMP, Cell Differentiation, Fibroblasts, Colforsin, Humans, Dinoprostone, Receptors, Prostaglandin E
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.